In hematological malignancies, theranostics is particularly promising due to the high expression of disease-specific antigens (e.g., Cluster of Differentiation (CD)20, CD38, CD45, CD123) that can serve as molecular targets for radiopharmaceuticals. This evidence concerns the gene IL3RA and hematologic disorder.